BNP Paribas Financial Markets Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Posted by Brian Himes on Jun 6th, 2026

BNP Paribas Financial Markets boosted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) by 1,275.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 475,749 shares of the company’s stock after purchasing an additional 441,156 shares during the quarter. BNP Paribas Financial Markets’ holdings in Dianthus Therapeutics were worth $19,606,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Intech Investment Management LLC acquired a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $247,000. Geode Capital Management LLC increased its stake in Dianthus Therapeutics by 26.1% during the fourth quarter. Geode Capital Management LLC now owns 676,658 shares of the company’s stock worth $27,890,000 after acquiring an additional 140,243 shares during the last quarter. Fisher Asset Management LLC acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $575,000. PSP Research LLC acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $524,000. Finally, Profund Advisors LLC acquired a new position in Dianthus Therapeutics during the 4th quarter worth $879,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Insider Transactions at Dianthus Therapeutics

In related news, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 349,551 shares of company stock worth $28,968,156 in the last three months. 3.02% of the stock is currently owned by company insiders.

Dianthus Therapeutics Stock Down 4.3%

Shares of DNTH stock opened at $80.51 on Friday. The business has a 50 day moving average of $87.31 and a two-hundred day moving average of $63.70. Dianthus Therapeutics, Inc. has a 52 week low of $16.64 and a 52 week high of $96.50. The company has a market cap of $4.40 billion, a P/E ratio of -19.49 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 9th. William Blair reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Wells Fargo & Company began coverage on Dianthus Therapeutics in a research report on Thursday, March 19th. They set an “overweight” rating and a $135.00 target price on the stock. Oppenheimer boosted their target price on Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $117.82.

Check Out Our Latest Research Report on Dianthus Therapeutics

About Dianthus Therapeutics

(Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.